Sweden, Like France, OKs Start of Masitinib Trial in Progressive MS
Feb. 7th, 2022 The Swedish Medical Products Agency has approved AB Science’s request to launch in the country a confirmatory…
Answering Viewers Questions: Highly Effective Multiple Sclerosis Medications
Click to Subscribe for the MS Beacon eNewsletter and MS educational events Visit our MS Learning Channel on YouTube:…
Stuart Schlossman
Novartis announces U.S. Court of Appeals for the Federal Circuit (CAFC) upholds validity of Gilenya® (fingolimod) dosage regimen patent
January 4, 2022 — Basel, January 4, 2022 — Today, Novartis announced that the U.S. Court of Appeals for the Federal…
Stuart Schlossman
Study: Anti-CD20 Therapies, Gilenya Lower Efficacy of COVID-19 Vaccines
Certain treatments for multiple sclerosis (MS) — specifically, anti-CD20 antibody therapies and Gilenya (fingolimod) — are likely to reduce the effectiveness of vaccines…
Stuart Schlossman
TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis
December 14, 2021 (Globe Newswire) Prescription Drug User Fee Act (PDUFA) goal date of September 28, 2022 TG Therapeutics, Inc.…
Stuart Schlossman
mRNA COVID-19 vaccines effective in patients with MS on disease-modifying therapies
December 3, 2021 Messenger RNA COVID-19 vaccination was effective among most patients with MS who used various disease-modifying therapies, according…
Stuart Schlossman
Relapse comparable among common DMTs for MS
Dimethyl fumarate and fingolimod appeared to have no significant difference in relapse rates, and rituximab appeared to have better relapse…
Stuart Schlossman
Timing of rituximab infusion not tied to risk for COVID-19 hospitalization
December 6, 2021 The timing of rituximab infusion or cumulative lifetime rituximab dose did not appear statistically significantly associated with…
Stuart Schlossman
Siponimod’s Efficacy on Secondary Progressive MS in Older age groups
October 28, 2021 – Le Hua, MD ranscript below. Le Hua, MD: The original EXPAND study had been presented, so…
Stuart Schlossman
Evaluate the efficacy and safety of alemtuzumab in CARE-MS II patients over 10 years
Knowing what MS can do to people and seeing these results who wouldn’t want to be treated with, or at…
Stuart Schlossman
